Business Model & Revenue
Marker is a Houston-based clinical-stage immuno-oncology company built on the multi-antigen recognizing (MAR)-T cell platform, exclusively licensed worldwide from Baylor College of Medicine. Its lead product, MT-601 (neldaleucel), is an autologous T-cell therapy that is not genetically modified: instead of engineering a single-antigen receptor like a CAR-T, Marker selectively expands tumor-specific T cells that recognize up to six antigens upregulated in lymphoma — Survivin, PRAME, WT-1, NY-ESO-1, SSX-2 and MAGEA4 — covering hundreds of epitopes and reducing the antigen-loss escape that drives relapse after CD19-directed therapy. Because the cells are not engineered, management believes manufacturing is simpler and cheaper than engineered approaches; Kincellis, a CDMO, handles technology transfer and cGMP production for APOLLO.
There is no commercial revenue and there may not be for years. The near-term economic model is almost unique among nano-cap biotechs: development funded by competitive non-dilutive awards — CPRIT, NIH/NCI, FDA's orphan-products program and the Department of War — with $2.7 million of grant income recognized in the first nine months of 2026, about 27% of operating expenses. Value inflection comes from clinical data (updated Phase 1 results this year, then the Phase 2 APOLLO readout path in post-CAR-T large B-cell lymphoma), not sales.
If MT-601 advances, the commercial model is a classic orphan indication: relapsed post-CAR-T LBCL is a small, desperate population with poor outcomes and established cell-therapy pricing benchmarks, and multi-antigen targeting would differentiate on escape resistance and manufacturing cost.
Financial Highlights
P&L Trend (no product revenue; grant income offsets spend)
| Metric | Q3 2026 | Q3 2025 | 9M 2026 | 9M 2025 |
|---|---|---|---|---|
| Net loss | ($1.8M) | ($2.0M) | ($6.8M) | ($10.5M) |
| Net loss per share | ($0.10) | ($0.12) | ($0.35) | ($0.75) |
| Grant income | $1.3M | $1.2M | $2.7M | $2.4M |
Nine-month R&D expense fell 33% year over year to $6.5 million, mainly on lower clinical-trial spend, while operating cash use totaled $7.6 million. Grant income now covers roughly a quarter of operating expenses.
Balance Sheet (September 30, 2026)
| Item | Amount |
|---|---|
| Cash and equivalents | $9.04M |
| Restricted cash | $0.39M |
| Grant receivable | $2.43M |
| Total current assets | $12.50M |
| Shares outstanding (11/13/26) | 16,673,127 |
Non-Dilutive Funding Stack (secured awards)
| Award | Amount | Purpose |
|---|---|---|
| CPRIT Product Development (Nov 2026) | $16.2M | Phase 2 APOLLO — MT-601 in post-CAR-T LBCL |
| U.S. Department of War (prior disclosure) | $4.2M | Lymphoma development |
| FDA Orphan Products (Sept 2026) | $2.6M | Phase 1 in locally advanced pancreatic cancer |
| NCI / NIH SBIR (incl. R44CA291521) | — | Phase 1 APOLLO support |
Guidance: No product revenue or financial guidance. Management estimates runway into Q2 2027 absent additional grant receipts; substantial doubt about going concern remains disclosed. Updated APOLLO clinical data expected later this year.
Competitive Landscape
Marker's niche is the salvage slot: patients whose large B-cell lymphoma has already failed CD19 CAR-T. Every competitor below is either the therapy MT-601 follows or the one it must beat for that patient.
- Gilead Sciences (GILD) — Yescarta/Tecartus: the CD19 CAR-T franchise that defines the frontline-relapsed standard MT-601 follows; also the benchmark for cell-therapy commercial execution.
- Bristol Myers Squibb (BMY) — Breyanzi: the competing CD19 CAR-T in LBCL; its relapse population is Marker's addressable market.
- Novartis (NVS) — Kymriah: the third approved CD19 CAR-T; same dynamic — every Kymriah relapse is a potential APOLLO enrollment.
- Roche (ROG.SW) and AbbVie/Genmab — CD20 bispecifics (Lunsumio/glofitamab class; Epkinly): off-the-shelf T-cell engangers approved or advancing in post-CAR-T relapse; the direct commercial rivals for the same salvage patients, with no manufacturing complexity.
- Allogeneic CAR-T programs (public and private): donated-cell engineered approaches chasing the same post-CAR-T slot with faster logistics.
Moats:
- Multi-antigen recognition — six targets and hundreds of epitopes versus single-antigen CAR-Ts, directly attacking the antigen-loss escape mechanism
- Non-genetically-modified manufacturing — simpler and lower-cost production than engineered cells, with a contracted cGMP CDMO already in place
- Baylor College of Medicine exclusive worldwide license plus a clinical history of more than 200 patients treated across MAR-T studies
- A funding moat no nano-cap peer has: state and federal grant capital — CPRIT, NCI, FDA and the Department of War — that pays for development without touching the share count
Catalysts
-
Updated APOLLO Phase 1 data — later this year: additional patients and response-durability updates on top of the 66% ORR / 50% CR in 12 evaluable NHL patients, with responses up to 24 months at the prior cutoff
-
Phase 2 APOLLO initiation in post-CAR-T LBCL: the CPRIT-funded registrational-pathway study in relapsed or refractory large B-cell lymphoma following CD19 CAR-T — the value-defining event
-
Grant cash conversion through 2027: CPRIT, Department of War ($4.2 million) and FDA ($2.6 million) receipts hitting the balance sheet as qualifying costs are incurred — the mechanism that retires the going-concern warning
-
FDA-funded pancreatic Phase 1: the $2.6 million orphan-products award supports a Phase 1 in locally advanced unresectable pancreatic cancer; initiation timing was unconfirmed in the Q3 filing, so a start would be incremental news
-
Data-driven partnership interest: positive updated Phase 1 results would put a cheap, grant-funded, multi-antigen asset in front of the same licensors who have paid up for post-CAR-T assets
Key Risks
- Going concern — $9.4 million of cash at September 30, disclosed runway into Q2 2027 and substantial doubt about the ability to continue; CPRIT grants reimburse incurred costs rather than arriving as lump sums, and $2.4 million of grant income already sits in receivables, so receipt timing can still force a raise
- Clinical — the 66% objective response rate and 50% complete response rest on 12 evaluable patients in a single-arm Phase 1; small-n cell-therapy response rates routinely compress as cohorts expand, and Phase 2 APOLLO has not yet started
- Financing and dilution — any gap between grant receipts and clinical spend forces equity issuance the going-concern language anticipates; the December 2025 private placement with pre-funded warrants shows the path of least resistance is a discounted deal
- Listing — the stock traded at $0.84-0.99 this week, below the $1.00 Nasdaq minimum bid threshold, exposing it to a deficiency process that historically ends in a reverse split
- Competitive — post-CAR-T LBCL is being commercialized now by CD20 bispecifics and next-generation CAR-Ts from Gilead, Bristol Myers Squibb, Novartis and Roche; MT-601 must demonstrate differentiation against entrenched off-the-shelf options to win the salvage slot
Our Thesis
The market cap forgot the funding stack. Marker's September 10-Q showed $9.4 million of cash, runway into Q2 2027 and substantial doubt about going concern — a fair reason the stock traded under $1. But since September the company has stacked a $2.6 million FDA orphan-products award on a previously disclosed $4.2 million Department of War lymphoma award, and now a $16.2 million CPRIT grant that survived a 207-application, 12-winner review of science, regulatory strategy, manufacturing and commercial potential. Pro forma cash of ≈$25.6 million against a ≈$16.5 million market cap means the pipeline — MT-601, a non-genetically-modified MAR-T therapy targeting six lymphoma antigens, exclusively licensed worldwide from Baylor College of Medicine — is priced below zero after grant-timing risk.
Our $1.65 target is a scenario blend, not a multiple. At 55%, CPRIT and DoW money funds the Phase 2 APOLLO start in post-CAR-T LBCL and updated Phase 1 data lands this year as promised; a grant-funded nano-cap with $25.6 million of tracked cash and a 66% ORR / 50% CR Phase 1 dataset deserves ≈$2.50, about 1.6x pro forma cash. At 45%, grant receipts lag spend — CPRIT grants reimburse incurred costs rather than arriving as lump sums, and $2.4 million already sits in receivables — forcing the dilution the going-concern language warns about, worth ≈$0.60. Blend: 0.55 × $2.50 + 0.45 × $0.60 ≈ $1.65, a 67% expected return that belongs in the speculative bucket.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.